JP2021528052A5 - - Google Patents
Info
- Publication number
- JP2021528052A5 JP2021528052A5 JP2020567827A JP2020567827A JP2021528052A5 JP 2021528052 A5 JP2021528052 A5 JP 2021528052A5 JP 2020567827 A JP2020567827 A JP 2020567827A JP 2020567827 A JP2020567827 A JP 2020567827A JP 2021528052 A5 JP2021528052 A5 JP 2021528052A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024007979A JP7741903B2 (ja) | 2018-06-25 | 2024-01-23 | 強力で選択的なインターロイキン模倣体のデノボ設計 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862689769P | 2018-06-25 | 2018-06-25 | |
| US62/689,769 | 2018-06-25 | ||
| US201862768733P | 2018-11-16 | 2018-11-16 | |
| US62/768,733 | 2018-11-16 | ||
| PCT/US2019/038703 WO2020005819A1 (en) | 2018-06-25 | 2019-06-24 | De novo design of potent and selective interleukin mimetics |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024007979A Division JP7741903B2 (ja) | 2018-06-25 | 2024-01-23 | 強力で選択的なインターロイキン模倣体のデノボ設計 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021528052A JP2021528052A (ja) | 2021-10-21 |
| JP2021528052A5 true JP2021528052A5 (https=) | 2024-01-31 |
| JPWO2020005819A5 JPWO2020005819A5 (https=) | 2024-01-31 |
Family
ID=67352582
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020567827A Pending JP2021528052A (ja) | 2018-06-25 | 2019-06-24 | 強力で選択的なインターロイキン模倣体のデノボ設計 |
| JP2024007979A Active JP7741903B2 (ja) | 2018-06-25 | 2024-01-23 | 強力で選択的なインターロイキン模倣体のデノボ設計 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024007979A Active JP7741903B2 (ja) | 2018-06-25 | 2024-01-23 | 強力で選択的なインターロイキン模倣体のデノボ設計 |
Country Status (13)
| Country | Link |
|---|---|
| US (8) | US10703791B2 (https=) |
| EP (1) | EP3810640A1 (https=) |
| JP (2) | JP2021528052A (https=) |
| KR (1) | KR20210025522A (https=) |
| CN (1) | CN112739713A (https=) |
| AU (1) | AU2019295637B2 (https=) |
| BR (1) | BR112020025287A2 (https=) |
| CA (1) | CA3102653A1 (https=) |
| IL (1) | IL279415A (https=) |
| MX (1) | MX2020014027A (https=) |
| PH (1) | PH12020552140A1 (https=) |
| SG (1) | SG11202011460YA (https=) |
| WO (1) | WO2020005819A1 (https=) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3737692A4 (en) | 2018-01-09 | 2021-09-29 | Elstar Therapeutics, Inc. | CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES |
| US12152073B2 (en) | 2018-03-14 | 2024-11-26 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| EP3810640A1 (en) * | 2018-06-25 | 2021-04-28 | University of Washington | De novo design of potent and selective interleukin mimetics |
| EP3818083A2 (en) | 2018-07-03 | 2021-05-12 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| EP3883956A1 (en) * | 2018-11-20 | 2021-09-29 | University of Washington | Split interleukin mimetics and their use |
| AU2020224681A1 (en) | 2019-02-21 | 2021-09-16 | Marengo Therapeutics, Inc. | Antibody molecules that bind to NKp30 and uses thereof |
| JP7710373B2 (ja) | 2019-02-21 | 2025-07-18 | マレンゴ・セラピューティクス，インコーポレーテッド | Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用 |
| JP2022553370A (ja) * | 2019-10-25 | 2022-12-22 | ネオルーキン セラピューティクス，インコーポレイティド | Ｉｌ－２受容体作動薬の投与方法 |
| BR112022012112A2 (pt) | 2019-12-20 | 2022-09-06 | Regeneron Pharma | Agonistas de il2 e métodos de uso dos mesmos |
| CN116234829A (zh) | 2020-01-03 | 2023-06-06 | 马伦戈治疗公司 | 抗tcr抗体分子及其用途 |
| EP4121449A2 (en) * | 2020-03-16 | 2023-01-25 | Neoleukin Therapeutics, Inc. | Interleukin-2 receptor beta (il-2rb) binding polypeptides |
| CN114380919B (zh) * | 2020-10-18 | 2024-06-25 | 北京志道生物科技有限公司 | 经修饰的il-2分子及其用途 |
| CN112266413A (zh) * | 2020-10-22 | 2021-01-26 | 中国人民解放军海军军医大学 | 扩增nk细胞并增强其杀伤活性的因子、饲养细胞系及方法 |
| MX2023011310A (es) | 2021-03-26 | 2023-10-05 | Innate Pharma | Anclajes de citocina para proteinas de celulas nk de union a nkp46. |
| BR112023025331A2 (pt) | 2021-06-09 | 2024-02-27 | Innate Pharma | Proteína multiespecífica, composição farmacêutica, célula recombinante, ácido nucleico ou conjunto de ácidos nucleicos, uso de uma proteína ou composição, métodos ou uso |
| WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
| WO2022258678A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a |
| TW202317623A (zh) | 2021-06-14 | 2023-05-01 | 美商再生元醫藥公司 | 基於il2之治療劑及其使用方法 |
| CN113603791A (zh) * | 2021-08-11 | 2021-11-05 | 厦门目青股权投资合伙企业(有限合伙) | 一种融合蛋白及其应用 |
| WO2023044318A2 (en) * | 2021-09-15 | 2023-03-23 | Neoleukin Therapeutics, Inc. | Interleukin-2 receptor βeta (il-2rβ) binding polypeptides |
| WO2023052541A1 (en) * | 2021-09-30 | 2023-04-06 | Imcheck Therapeutics | Combination of an anti-btn3a activating antibody and an il-2 agonist for use in therapy |
| EP4460512A4 (en) * | 2022-01-07 | 2026-01-14 | Cure Genetics Co Ltd | NEW INTERLEUKIN-2 POLYPEPTIDES |
| IL314226A (en) * | 2022-01-11 | 2024-09-01 | Outpace Bio Inc | Designed cytokine compositions and methods of use |
| AU2023215393A1 (en) * | 2022-02-04 | 2024-08-15 | The Board Of Trustees Of The Leland Stanford Junior University | Surrogate cytokine polypeptides |
| CN114927160B (zh) * | 2022-03-03 | 2024-09-27 | 北京晶泰科技有限公司 | 热点残基和靶点蛋白复合物结构的生成方法及装置 |
| CN115124627B (zh) * | 2022-06-20 | 2026-03-17 | 中国人民解放军海军军医大学 | 一种自分泌IL2Rβγ激动剂的MSLN-CAR-NK细胞及其应用 |
| CN114773433B (zh) * | 2022-06-23 | 2022-09-06 | 北京肿瘤医院(北京大学肿瘤医院) | 一种cd25靶向多肽、分子探针及应用 |
| CN119451978A (zh) * | 2022-07-01 | 2025-02-14 | 神经基因治疗公司 | Neo-2/15变体及其用于优先刺激T调节细胞的用途 |
| WO2024177972A2 (en) * | 2023-02-20 | 2024-08-29 | The Wistar Institute Of Anatomy And Biology | Antibody-cytokine chimeras |
| EP4722235A1 (en) * | 2023-05-24 | 2026-04-08 | Nantong Yichen Biopharma. Co. Ltd. | Polypeptide, and conjugate and use thereof |
| CN119661643A (zh) * | 2024-12-17 | 2025-03-21 | 北京肿瘤医院(北京大学肿瘤医院) | 一种cd25靶向环状多肽、分子探针及应用 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5229109A (en) | 1992-04-14 | 1993-07-20 | Board Of Regents, The University Of Texas System | Low toxicity interleukin-2 analogues for use in immunotherapy |
| US6955807B1 (en) | 1998-05-15 | 2005-10-18 | Bayer Pharmaceuticals Corporation | IL-2 selective agonists and antagonists |
| US6168785B1 (en) | 1998-07-16 | 2001-01-02 | Institut Pasteur | Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents |
| ES2300280T3 (es) | 1999-12-08 | 2008-06-16 | Amgen Inc. | Moleculas de tipo interferon y usos de las mismas. |
| GB0019638D0 (en) * | 2000-08-09 | 2000-09-27 | European Molecular Biology Lab Embl | Peptide mimetics |
| MXPA03011158A (es) * | 2001-06-07 | 2004-02-27 | Wyeth Corp | Estructura de solucion de il - 13 y sus usos. |
| ATE442377T1 (de) * | 2003-08-07 | 2009-09-15 | Hoffmann La Roche | Ra antigene peptide |
| CN1930300A (zh) | 2004-03-05 | 2007-03-14 | 希龙公司 | 预测患者治疗药物耐受性的体外试验系统 |
| BRPI0617688A2 (pt) * | 2005-10-21 | 2011-06-07 | Hoffmann La Roche | método para expressão recombinante de um polipeptìdeo |
| US9676871B2 (en) | 2010-11-05 | 2017-06-13 | Pfizer Inc. | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| US9428567B2 (en) | 2010-12-22 | 2016-08-30 | The Board Of Trustees Of The Leland Stanford Junior University | Antagonists of interleukin-2 receptor |
| US9844582B2 (en) | 2012-05-22 | 2017-12-19 | Massachusetts Institute Of Technology | Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents |
| SG10201913396RA (en) * | 2014-02-28 | 2020-03-30 | Ichnos Sciences SA | Expression constructs and methods for selecting host cells expressing polypeptides |
| WO2015164815A1 (en) | 2014-04-24 | 2015-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Superagonists, partial agonists and antagonists of interleukin-2 |
| US9777070B2 (en) | 2014-04-30 | 2017-10-03 | Pfizer Inc | Anti-PTK7 antibody-drug conjugates |
| WO2016025385A1 (en) | 2014-08-11 | 2016-02-18 | Delinia, Inc. | Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| AR105616A1 (es) | 2015-05-07 | 2017-10-25 | Lilly Co Eli | Proteínas de fusión |
| WO2018153865A1 (en) | 2017-02-24 | 2018-08-30 | Philogen S.P.A. | Immunoconjugates with optimized linkers and orientation |
| ES2894731T3 (es) | 2017-03-15 | 2022-02-15 | Silverback Therapeutics Inc | Compuestos de benzazepina, conjugados y usos de los mismos |
| EP3810640A1 (en) * | 2018-06-25 | 2021-04-28 | University of Washington | De novo design of potent and selective interleukin mimetics |
| EP3883585A4 (en) * | 2018-11-20 | 2022-12-14 | Innovative Cellular Therapeutics Holdings, Ltd. | MODIFIED CELL EXPRESSING THERAPEUTIC AND USES THEREOF |
| EP3883956A1 (en) * | 2018-11-20 | 2021-09-29 | University of Washington | Split interleukin mimetics and their use |
| JP2022553370A (ja) | 2019-10-25 | 2022-12-22 | ネオルーキン セラピューティクス，インコーポレイティド | Ｉｌ－２受容体作動薬の投与方法 |
| US20230331858A1 (en) | 2019-12-24 | 2023-10-19 | Neoleukin Therapeutics, Inc. | Combination therapy using an il-2 receptor agonist and an immune checkpoint inhibitor |
| CN111040981A (zh) * | 2019-12-26 | 2020-04-21 | 南昌大学 | 表达重组IL-2的重组大肠杆菌Nissle 1917及其功能验证方法 |
| EP4121449A2 (en) | 2020-03-16 | 2023-01-25 | Neoleukin Therapeutics, Inc. | Interleukin-2 receptor beta (il-2rb) binding polypeptides |
-
2019
- 2019-06-24 EP EP19742110.0A patent/EP3810640A1/en active Pending
- 2019-06-24 CA CA3102653A patent/CA3102653A1/en active Pending
- 2019-06-24 BR BR112020025287-5A patent/BR112020025287A2/pt unknown
- 2019-06-24 JP JP2020567827A patent/JP2021528052A/ja active Pending
- 2019-06-24 KR KR1020207035974A patent/KR20210025522A/ko active Pending
- 2019-06-24 SG SG11202011460YA patent/SG11202011460YA/en unknown
- 2019-06-24 MX MX2020014027A patent/MX2020014027A/es unknown
- 2019-06-24 CN CN201980042036.7A patent/CN112739713A/zh active Pending
- 2019-06-24 AU AU2019295637A patent/AU2019295637B2/en active Active
- 2019-06-24 WO PCT/US2019/038703 patent/WO2020005819A1/en not_active Ceased
- 2019-09-16 US US16/572,038 patent/US10703791B2/en active Active
-
2020
- 2020-06-18 US US16/905,669 patent/US11117944B2/en active Active
- 2020-06-23 US US16/909,185 patent/US10844105B2/en active Active
- 2020-06-23 US US16/909,210 patent/US11401313B2/en active Active
- 2020-12-11 PH PH12020552140A patent/PH12020552140A1/en unknown
- 2020-12-13 IL IL279415A patent/IL279415A/en unknown
-
2021
- 2021-09-13 US US17/473,731 patent/US11655278B2/en active Active
-
2022
- 2022-03-18 US US17/698,553 patent/US12240880B2/en active Active
-
2023
- 2023-03-21 US US18/187,639 patent/US12227553B2/en active Active
-
2024
- 2024-01-23 JP JP2024007979A patent/JP7741903B2/ja active Active
-
2025
- 2025-01-16 US US19/025,380 patent/US20250171514A1/en active Pending